Koji Takai

2.7k total citations
75 papers, 2.1k citations indexed

About

Koji Takai is a scholar working on Hepatology, Epidemiology and Physiology. According to data from OpenAlex, Koji Takai has authored 75 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Hepatology, 43 papers in Epidemiology and 23 papers in Physiology. Recurrent topics in Koji Takai's work include Liver Disease Diagnosis and Treatment (41 papers), Liver Disease and Transplantation (28 papers) and Nutrition and Health in Aging (22 papers). Koji Takai is often cited by papers focused on Liver Disease Diagnosis and Treatment (41 papers), Liver Disease and Transplantation (28 papers) and Nutrition and Health in Aging (22 papers). Koji Takai collaborates with scholars based in Japan and United States. Koji Takai's co-authors include Masahito Shimizu, Kenji Imai, Hisataka Moriwaki, Tatsunori Hanai, Makoto Shiraki, Atsushi Suetsugu, Sachiyo Ohnishi, Kayoko Nishimura, Takayasu Ideta and Tsuneyuki Miyazaki and has published in prestigious journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Koji Takai

71 papers receiving 2.0k citations

Peers

Countries citing papers authored by Koji Takai

Since Specialization

Citations

This map shows the geographic impact of Koji Takai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Koji Takai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Koji Takai more than expected).

Fields of papers citing papers by Koji Takai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Koji Takai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Koji Takai. The network helps show where Koji Takai may publish in the future.

Co-authorship network of co-authors of Koji Takai

This figure shows the co-authorship network connecting the top 25 collaborators of Koji Takai. A scholar is included among the top collaborators of Koji Takai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Koji Takai. Koji Takai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Excessive Visceral Adipose Tissue Accumulation Increases the Risk of Recurrence and Mortality After Curative Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Associated Hepatocellular Carcinoma 2025 ·Hepatology Research ·Kenji Imai, Koji Takai, (unknown), (unknown), (unknown), Takao Miwa, Tatsunori Hanai, Hiroyasu Sakai, Yohei Shirakami, Atsushi Suetsugu, Masahito Shimizu	1
2	Psoas Muscle Index as an Independent Predictor of Survival in Patients with Hepatocellular Carcinoma Receiving Systemic Targeted Therapy 2025 ·Cancers ·Kenji Imai, Koji Takai, (unknown), (unknown), Takao Miwa, Tatsunori Hanai, Hiroyasu Sakai, Yohei Shirakami, Atsushi Suetsugu, Masahito Shimizu	1
3	Acute kidney injury development is associated with mortality in Japanese patients with cirrhosis: impact of amino acid imbalance 2024 ·Journal of Gastroenterology ·Takao Miwa, (unknown), Tatsunori Hanai, (unknown), (unknown), Kenji Imai, Koji Takai, Makoto Shiraki, (unknown), Masahito Shimizu	7
4	Unresectable Combined Hepatocellular-cholangiocarcinoma Treated with Combination Therapy Consisting of Durvalumab Plus Tremelimumab 2024 ·Internal Medicine ·(unknown), Kenji Imai, Takao Miwa, Tatsunori Hanai, Atsushi Suetsugu, Koji Takai, Natsuko Suzui, Tatsuhiko Miyazaki, Masahito Shimizu	1
5	Lenvatinib Exacerbates the Decrease in Skeletal Muscle Mass in Patients with Hepatocellular Carcinoma, Whereas Atezolizumab Plus Bevacizumab Does Not 2024 ·Cancers ·Kenji Imai, Koji Takai, (unknown), Takao Miwa, Tatsunori Hanai, Atsushi Suetsugu, Masahito Shimizu	2
6	Dysphagia risk evaluated by the Eating Assessment Tool-10 is associated with health-related quality of life in patients with chronic liver disease 2024 ·Nutrition ·Takao Miwa, Tatsunori Hanai, (unknown), (unknown), Kayoko Nishimura, (unknown), (unknown), Kenji Imai, Yohei Shirakami, (unknown), Koji Takai, Masahito Shimizu	1
7	Adverse Events in Targeted Therapy for Unresectable Hepatocellular Carcinoma Predict Clinical Outcomes 2024 ·Cancers ·Kenji Imai, Koji Takai, (unknown), (unknown), Takao Miwa, Tatsunori Hanai, Atsushi Suetsugu, Masahito Shimizu	0
8	Vitamin D deficiency stratifies the risk of covert and overt hepatic encephalopathy in patients with cirrhosis: A retrospective cohort study 2024 ·Clinical Nutrition ESPEN ·Takao Miwa, Tatsunori Hanai, (unknown), Kayoko Nishimura, Yuki Sahashi, (unknown), Kenji Imai, Yohei Shirakami, Atsushi Suetsugu, Koji Takai, Masahito Shimizu	2
9	Prevalence, association, and prognostic significance of polypharmacy and sarcopenia in patients with liver cirrhosis 2023 ·JGH Open ·Tatsunori Hanai, Kayoko Nishimura, Takao Miwa, (unknown), Kenji Imai, Atsushi Suetsugu, Koji Takai, Masahito Shimizu	3
10	A case of A20 haploinsufficiency complicated by autoimmune hepatitis 2023 ·Hepatology Research ·(unknown), Takao Miwa, (unknown), Tatsunori Hanai, Kenji Imai, Koji Takai, (unknown), Tomohiro Hori, Hidenori Ohnishi, (unknown), Ayumi Niwa, Tatsuhiko Miyazaki, Masahito Shimizu	2
11	Effect of Selenium Deficiency on the Development of Overt Hepatic Encephalopathy in Patients with Chronic Liver Disease 2023 ·Journal of Clinical Medicine ·(unknown), Tatsunori Hanai, Takao Miwa, (unknown), Kenji Imai, Atsushi Suetsugu, Koji Takai, Masahito Shimizu	2
12	Usefulness of the Global Leadership Initiative on Malnutrition criteria to predict sarcopenia and mortality in patients with chronic liver disease 2022 ·Hepatology Research ·Takao Miwa, Tatsunori Hanai, Kayoko Nishimura, (unknown), (unknown), (unknown), Kenji Imai, Atsushi Suetsugu, Koji Takai, Masahito Shimizu	32
13	Usefulness of the Trabecular Bone Score in Assessing the Risk of Vertebral Fractures in Patients with Cirrhosis 2022 ·Journal of Clinical Medicine ·(unknown), Tatsunori Hanai, Kayoko Nishimura, Takao Miwa, (unknown), Kenji Imai, Atsushi Suetsugu, Koji Takai, Masahito Shimizu	4
14	A simple covert hepatic encephalopathy screening model based on blood biochemical parameters in patients with cirrhosis 2022 ·PLoS ONE ·Takao Miwa, Tatsunori Hanai, Kayoko Nishimura, (unknown), (unknown), Kenji Imai, Atsushi Suetsugu, Koji Takai, Mayumi Yamamoto, Masahito Shimizu	8
15	Changes in ALBI Score and PIVKA-II within Three Months after Commencing Atezolizumab Plus Bevacizumab Treatment Affect Overall Survival in Patients with Unresectable Hepatocellular Carcinoma 2022 ·Cancers ·(unknown), Kenji Imai, Koji Takai, Takao Miwa, Tatsunori Hanai, Yoichi Nishigaki, Hideki Hayashi, Takahiro Kochi, Shogo Shimizu, Junji Nagano, Soichi Iritani, Atsushi Suetsugu, Masahito Shimizu	7
16	Higher Accumulation of Visceral Adipose Tissue Is an Independent Risk Factor for Hepatocellular Carcinoma among Viral Hepatitis Patients with Non-Cirrhotic Livers 2021 ·Cancers ·Kenji Imai, Koji Takai, Takao Miwa, (unknown), Tatsunori Hanai, Yohei Shirakami, Atsushi Suetsugu, Masahito Shimizu	6
17	Handgrip strength stratifies the risk of covert and overt hepatic encephalopathy in patients with cirrhosis 2021 ·Journal of Parenteral and Enteral Nutrition ·Takao Miwa, Tatsunori Hanai, Kayoko Nishimura, (unknown), (unknown), Kenji Imai, Atsushi Suetsugu, Koji Takai, Makoto Shiraki, Masahito Shimizu	22
18	Increased Visceral Adipose Tissue and Hyperinsulinemia Raise the Risk for Recurrence of Non-B Non-C Hepatocellular Carcinoma after Curative Treatment 2021 ·Cancers ·Kenji Imai, Koji Takai, Takao Miwa, (unknown), Tatsunori Hanai, Makoto Shiraki, Atsushi Suetsugu, Masahito Shimizu	13
19	Rapid Depletions of Subcutaneous Fat Mass and Skeletal Muscle Mass Predict Worse Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib 2019 ·Cancers ·Kenji Imai, Koji Takai, Takao Miwa, (unknown), Tatsunori Hanai, Atsushi Suetsugu, Makoto Shiraki, Masahito Shimizu	38
20	Acyclic Retinoid Inhibits Diethylnitrosamine-Induced Liver Tumorigenesis in Obese and Diabetic C57BLKS/J- +Lepr db /+Lepr db Mice 2010 ·Cancer Prevention Research ·Masahito Shimizu, Hiroyasu Sakai, Yohei Shirakami, Junpei Iwasa, Yoichi Yasuda, Masaya Kubota, Koji Takai, Hisashi Tsurumi, Takuji Tanaka, Hisataka Moriwaki	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact